Robert A Baiocchi

8591892, Nov 26, 2013

Jul 18, 2012

13/551866

Lapo Alinari - Dublin OH, US
Robert A. Baiocchi - Dublin OH, US
Natarajan Muthusamy - Galloway OH, US
Hans J. Hansen - Picayune MS, US
David M. Goldenberg - Mendham NJ, US

The Ohio State University - Columbus OH
Immunomedics, Inc. - Morris Plains NJ

A61K 39/395

4241301

Disclosed herein are methods and compositions comprising fingolimod and anti-CD74 antibodies or fragments thereof. In preferred embodiments, the fingolimod increases the expression of CD74 in target cells and increases the sensitivity of the cells to the cytotoxic effects of the anti-CD74 antibodies. The compositions and methods are of use to treat diseases involving CD74 cells, such as cancer cells, autoimmune disease cells or immune dysfunction disease cells.

20070196389, Aug 23, 2007

Nov 17, 2006

11/561363

Michael Caligiuri - Columbus OH, US
Robert Baiocchi - Dublin OH, US

The Ohio State University Research Foundation - Columbus OH

A61K 39/25
A61K 48/00
C12N 15/86
C12N 7/00
A61K 39/245

424229100, 514044000, 424230100, 435005000, 435456000, 435235100, 435325000

Methods of vaccination to prevent virus-associated diseases, which methods generally result in an increase of virus-specific memory T cells that provide or restore host immunity and result in control of the viral-associated disease process. Polypeptides and DNA sequences for achieving these results are also described. In some embodiments, the virus is Epstein-Barr virus.

20090004182, Jan 1, 2009

Oct 12, 2005

11/577111

Robert A. Baiocchi - Columbus OH, US
Michael A. Caligiuri - Columbus OH, US
Anne M. Van Buskirk - Westerville OH, US

THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION - Columbus OH

A61K 39/395
C12Q 1/68
C12Q 1/02

4241331, 4241581, 4241721, 435 6, 435 29

The disclosure relates to methods to prevent, treat, or slow the progression viral-associated lymphoproliferative disorders, EBV-associated lymphoproliferative disorders, and post-transplant lymphoproliferative disorders. In the methods, a TGF-β antagonist, e.g., an anti-TGF-β antibody is administered to a subject. Methods for treating viral-associated lymphoproliferative disorders and for enhancing T-cell responsiveness to a viral-associated lymphoproliferative disorder by administering a TGF-β antagonist are also described.

20110281950, Nov 17, 2011

May 11, 2011

13/105576

Robert A. Baiocchi - Dublin OH, US

A61K 31/167
A61P 35/00

514575

Pharmaceutical compositions including an HDAC inhibitor and a pharmaceutically acceptable carrier wherein the HDAC inhibitor is present in an amount sufficient to achieve a plasma concentration from about 100 nM to about 2 uM and methods of treatment using the same. Pharmaceutical compositions including an HDAC inhibitor and a pharmaceutically acceptable carrier wherein the HDAC inhibitor is present in an amount from 0.1 mg to 100 mg. Pharmaceutical compositions including an HDAC inhibitor and a pharmaceutically acceptable carrier, wherein the concentration of the HDAC inhibitor is sufficient to decrease the relative viability of lymphoblastoid cells by at least about 50 percent and/or is sufficient to decrease the proliferation of lymphoblastoid cells by at least about 60 percent and/or is sufficient to decrease the relative viability of peripheral blood mononuclear cells by less than about 50 percent and methods of treatment using the same.

20130059892, Mar 7, 2013

Dec 22, 2010

13/518828

Robert Baiocchi - Dublin OH, US
Chenglong Li - Dublin OH, US
Pui Kai Li - Galloway OH, US
Fengting Yan - Columbus OH, US

The Ohio State University Research Foundation - Columbus

A61K 31/4439
C07D 401/14
A61P 35/00
C07D 401/12

514339, 5462767

Disclosed herein are compositions and methods for cancer detection and treatment. Compounds that inhibit PRMT5 are contemplated, as are pharmaceutical compositions comprising a therapeutically effective amount of at least one PRMT5 inhibitor. In some embodiments pharmaceutical compositions further comprising at least one HDAC inhibitor are contemplated. Methods of treating disorders in a mammal by inhibiting PRMT5 by administering to a mammal, a therapeutically effective amount of a PRMT5 inhibitor are also disclosed.

60428260, Mar 28, 2000

Nov 14, 1997

8/969881

Michael A. Caligiuri - Columbus OH
Robert B. Baiocchi - Columbus OH

Health Research, Inc. - Buffalo NY

A61K 39395
A61K 3816
C12P 2108
C07K 1600

4241301

A method for treating a primary central nervous system lymphoma in an individual relates to administering intrathecally or intralesionally a therapeutically effective amount of a Fas-cross-linking composition thereby inducing the lymphoma cells to undergo Fas-mediated cytotoxicity. The Fas-cross-linking composition may be an agonist anti-human Fas monoclonal antibody or fragments thereof, soluble Fas-ligand (Fas-L), and a combination thereof. In another embodiment, the lymphoma is pretreated with a composition that enhances Fas-mediated cytotoxicity induced by a Fas-cross-linking composition, followed by treatment with the Fas-cross-linking composition.

20210393683, Dec 23, 2021

Oct 22, 2018

16/755745

- South San Francisco CA, US
Robert Baiocchi - Dublin OH, US

Atara Biotherapeutics, Inc. - South San Francisco CA

A61K 35/17
A61P 35/00

Provided herein are methods of treating a solid malignant tumor using antigen-specific T cells and methods of managing tumor flare in treatment of a solid malignant tumor using antigen-specific T cells. The methods provided herein improve the safety of treatment by informing the patient about the potential risks for tumor flare, telling the patient to contact his or her physician if tumor swelling occurs, counseling a patient with Waldeyer's ring lymphadenopathy to contact his or her physician if shortness of breath or stridor occurs, or grading and managing tumor flare developed in the patient.

20140255432, Sep 11, 2014

Jul 27, 2012

14/235371

Robert A. Baiocchi - Dublin OH, US
David M. Lucas - Hilliard OH, US
Douglas Kinghorn - Columbus OH, US
Michael Grever - Powell OH, US

OHIO STATE INNOVATION FOUNDATION - Columbus OH

A61K 31/357
A61K 45/06

4241741, 514452, 4242771, 514 44 R, 514 193

Disclosed herein are treatment methods, vaccination methods, compositions, co-therapeutic methods, combination therapeutic compositions and kits comprising silvestrol and silvestrol analogs alone or in combination with therapeutic and preventative therapies. Disclosed herein are also methods, compositions and kits that can be used to treat cancer, viral infections, to modulate the immune system or as preventative therapies.